Recently, outgoing Minister Ernst Kuipers (VWS) published the research report ‘Qualitative in-depth analysis of gaps in drug development‘ brought to the attention of the House of Representatives, in which ReumaNederland also contributed. There are plenty of gaps, including for people with osteoarthritis.
One of the most important factors that play a role in drug development is financial return. The development of new medicines is also partly dependent on the willingness of governments and insurers to pay for them. Unfortunately, this is not always in line with social needs, the report concludes.
The need for new treatment options for osteoarthritis is great. The burden of disease is immense and the population is large and growing. Osteoarthritis has many (indirect) effects on other aspects of health. Currently, there are only medicines that combat symptoms.
In the past, a lot has been invested in the development of a generic treatment for osteoarthritis. It is now known that osteoarthritis does not have one face, but has many manifestations. All these forms require their own treatment. To make this possible, good diagnostics are needed, such as advanced imaging or the use of biomarkers. The report argues that there should be more guidance in the field of research into this.
Bron:
2023-09-20 09:49:08
#Closing #gaps #development #drugs #osteoarthritis #MedNet
